Description ABT-869 is a small molecule vascular endothelial growth factor (VEGF) receptor-based kinase inhibitor that is designed to suppress tumor growth by preventing the formation of new blood vessels that supply the tumor with oxygen and nutrients and by inhibiting key angiogenic signaling pathways.

Development Status Phase II clinical trials evaluating ABT-869 for hepatocellular (liver) carcinoma, metastatic breast cancer, metastatic colorectal cancer, metastatic non-small cell lung cancer, and advanced renal cell carcinoma are ongoing or planned. A Phase I clinical trial evaluating ABT-869 in combination with Tarceva for second-line metastatic non-small cell lung cancer is planned.

This molecule is being developed in collaboration with Abbott.

Additional Information on Clinical Trials For inquiries about our clinical trials, please submit a request through our information request form or call (888) 662-6728.

National Institutes of Health Website: www.clinicaltrials.gov

October 2008